CureVac GmbH, which is developing therapeutic vaccines against cancer, has raised €27.6 million from dievini Hopp BioTech holding GmbH, the investment company of Dietmar Hopp. The company has a compound for prostate cancer in Phase 2a. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
